• 重慶醫(yī)科大學(xué)臨床醫(yī)學(xué)院普外科(重慶 630042);

作者自1986年以來(lái)用碘油阿霉素乳劑(A/L)導(dǎo)向栓塞化療治療中晚期肝癌84例，并與采用肝動(dòng)脈或合并門(mén)靜脈灌注阿霉素的對(duì)照組24例進(jìn)行比較。結(jié)果表明，治療組癥狀改善率達(dá)86.1%，AFP下降率達(dá)75%，腫瘤縮小率達(dá)79.2%。治療后平均生存期為10.3月，明顯優(yōu)于對(duì)照組(5.6月)(P lt;0.001)。半年及1、2、3年累計(jì)生存率分別為89.3%、43.4%、13.5%和3.8%，均明顯高于對(duì)照組(半年51.2%、1年11.5%，無(wú)2年以上生存者)(P lt;0.01)，其中3例難以切除之肝癌經(jīng)本法治療后獲得二期切除，術(shù)后生存期明顯延長(zhǎng)。A/L灌注后合并明膠海綿中央栓塞的治療方案可以提高單純A/L灌注化療的療效。肝癌切除后再插管栓塞化療不僅可以鞏固治療效果，而且便于觀察隨訪。

引用本文： 羅億治,馬紹華,方開(kāi)先,王濟(jì)明,劉啟富,馬永臣. 碘油阿霉素乳劑導(dǎo)向栓塞化療治療中晚期原發(fā)性肝癌84例報(bào)告. 中國(guó)普外基礎(chǔ)與臨床雜志, 1995, 2(1): 17-20. doi: 復(fù)制

1. Yamada R, Sato M, Kawaibata M, et al. hepatic artery embolization in 120 patients with unresectable hepatoma, Radiology, 193;148(2)):397.
2. 湯釗猷，楊秉輝主編.原發(fā)性肝癌的研究與進(jìn)展.上海：上海醫(yī)科大學(xué)出版社，1990：7.
3. Nakakuma K, Tachiro S, Uemura K, et al. An attempt for increasing effects of hepatic artery ligation for advanced hepatoma ( in Japanese). Jap Deutsche Med Beriehte, 1979;24(4):675.
4. Komno T, Maeda H, Lwai K, et al. Effect of artery administration of high molecular anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a prefiminary report. Eur J Cancer Clin Oncol, 1983;19:1053.
5. Lwai K, Hiroshi M, Konno T, et al. Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effec image. Cancer Research, 194;44(2):2115.
6. Bookslein JJ, Cho KJ, Divis GB, et al. Arterioportal communications: Obervations transsinusoidal and transvasal types1. Radiology, 1982;142(3):581.
7. Kanematsu T, Turuto T, Takenaka K, et al. A 5-year experience of lipiodolization: Selective regional chmenotherapy for 200 patients with hepatocellular carcinoma. Hepatology, 1989;10(1):98.
8. Novell JR, Markham NI, Hobbs EF. New hopy in irresectable hepatoma? Hepatogastroenterol, 1989;30(4):258.
  1. 1. Yamada R, Sato M, Kawaibata M, et al. hepatic artery embolization in 120 patients with unresectable hepatoma, Radiology, 193;148(2)):397.
  2. 2. 湯釗猷，楊秉輝主編.原發(fā)性肝癌的研究與進(jìn)展.上海：上海醫(yī)科大學(xué)出版社，1990：7.
  3. 3. Nakakuma K, Tachiro S, Uemura K, et al. An attempt for increasing effects of hepatic artery ligation for advanced hepatoma ( in Japanese). Jap Deutsche Med Beriehte, 1979;24(4):675.
  4. 4. Komno T, Maeda H, Lwai K, et al. Effect of artery administration of high molecular anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a prefiminary report. Eur J Cancer Clin Oncol, 1983;19:1053.
  5. 5. Lwai K, Hiroshi M, Konno T, et al. Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effec image. Cancer Research, 194;44(2):2115.
  6. 6. Bookslein JJ, Cho KJ, Divis GB, et al. Arterioportal communications: Obervations transsinusoidal and transvasal types1. Radiology, 1982;142(3):581.
  7. 7. Kanematsu T, Turuto T, Takenaka K, et al. A 5-year experience of lipiodolization: Selective regional chmenotherapy for 200 patients with hepatocellular carcinoma. Hepatology, 1989;10(1):98.
  8. 8. Novell JR, Markham NI, Hobbs EF. New hopy in irresectable hepatoma? Hepatogastroenterol, 1989;30(4):258.